• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Isotope maker Shine Medical raises $50m from Oaktree Capital

Isotope maker Shine Medical raises $50m from Oaktree Capital

October 9, 2019 By Sean Whooley

Shine Medical TechnologiesShine Medical Technologies said this week that it closed a $50 million financing round from Oaktree Capital Management for the construction of a medical isotope production facility and commercialization of its products.

The Janesville, Wis.-based company expects construction on the plant to be completed in 2021, with commercial-scale isotope production slated to begin the following year. Shine said its facility will be capable of supplying more than one-third of the global demand for molybdenum-99 isotopes.

In 2016 the U.S. Nuclear Regulatory Commission cleared the company to build the facility. It was the first such clearance since 1960, according to the company.

Along with Mo-99, Shine said it plans to use the funds to commercialize lutetium-177, a therapeutic isotope used to treat neuroendocrine cancers. The company has an agreement with the Czech Academy of Sciences’ Institute of Organic Chemistry & Biochemistry that provides Shine with a global exclusive license to a separation technology that the company will use to produce non-carrier-added Lu-177, which it said should provide the highest therapeutic efficacy.

Shine will add the $50 million to the $18 million it added in June. The company also raised $27.2 million in January 2017 and another $29.3 million in April 2017.

“We are excited to welcome Oaktree to Shine’s growing list of top-tier institutional investors,” Shine founder & CEO Greg Piefer said in prepared remarks. “Oaktree has broad expertise in complex infrastructure projects like our medical isotope facility. It joins Deerfield Management, a leading health care investment firm, as one of our key partners. Oaktree and Deerfield will help us deliver on Shine’s value proposition, including the completion of our isotope production facility and the development of our therapeutics business. Their participation validates the strength of our business case, team and vision for bringing our lifesaving products to market.”

“Shine is an outstanding company with a strong management team, exceptional technology and compelling story,” added Oaktree managing director Milwood Hobbs Jr. “The need for Shine’s medical isotope production facility is profound, as millions of patients are affected each year by the ongoing shortage of Mo-99. Oaktree is confident Shine will play a major role in ending that shortage and we are pleased to support Shine’s production facility construction.”

“Oaktree is pleased to be a partner with Shine as it executes a growth strategy that includes commercializing therapeutic isotopes and constructing a production facility in Europe,” said Oaktree SVP Aman Kumar. “The global market for therapeutic isotopes, including Lu-177, continues to grow rapidly and Shine is well positioned to capture significant value in that market. We are equally as excited by Shine’s commitment to Europe, where the current isotope producers are expected to stop production during the next several years.”

Filed Under: Funding Roundup, Radiosurgery/Radiation therapy Tagged With: Shine Medical Technologies

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy